Treatment with AAV9‐2J2 remarkably decreased the AF inducibility in AAC mice (1/6, 16.6%, Figure 6B), whereas GW9662 moderately abolished the effect of AAV9‐CYP2J2 in AAC mice (3/6, 50%, Figure 6B). This evidence concerns the gene CYP2J2 and atrial fibrillation.